Pharmicell (005690) - Total Liabilities

Latest as of September 2025: ₩19.60 Billion KRW ≈ $13.28 Million USD

Based on the latest financial reports, Pharmicell (005690) has total liabilities worth ₩19.60 Billion KRW (≈ $13.28 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Pharmicell long-term investment allocation to see how much of total assets are deployed in long-term investments.

Pharmicell - Total Liabilities Trend (2010–2024)

This chart illustrates how Pharmicell's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Pharmicell.

Pharmicell Competitors by Total Liabilities

The table below lists competitors of Pharmicell ranked by their total liabilities.

Company	Country	Total Liabilities
Automotive Properties Real Estate Investment Trust TO:APR-UN	Canada	CA$696.04 Million
MMTEC Inc NASDAQ:MTC	USA	$3.90 Million
Bank Mestika Dharma Tbk JK:BBMD	Indonesia	Rp11.23 Trillion
ChoiceOne Financial Services Inc NASDAQ:COFS	USA	$3.92 Billion
Guangxi Fenglin Wood Industry Group Co Ltd SHG:601996	China	CN¥971.44 Million
Tadiran Hldg TA:TDRN	Israel	ILA1.30 Billion
Jiangsu Baoli Asphalt SHE:300135	China	CN¥586.32 Million
Chorus Aviation Inc TO:CHR	Canada	CA$816.42 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Pharmicell's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Pharmicell's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	10.82	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.18	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.15	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Pharmicell's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Pharmicell (2010–2024)

The table below shows the annual total liabilities of Pharmicell from 2010 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩12.83 Billion ≈ $8.69 Million	+5.80%
2023-12-31	₩12.12 Billion ≈ $8.21 Million	-63.25%
2022-12-31	₩32.98 Billion ≈ $22.35 Million	+8.28%
2021-12-31	₩30.46 Billion ≈ $20.64 Million	+141.01%
2020-12-31	₩12.64 Billion ≈ $8.57 Million	+7.60%
2019-12-31	₩11.75 Billion ≈ $7.96 Million	+1.03%
2018-12-31	₩11.63 Billion ≈ $7.88 Million	+49.86%
2017-12-31	₩7.76 Billion ≈ $5.26 Million	+5.44%
2016-12-31	₩7.36 Billion ≈ $4.99 Million	-56.58%
2013-12-31	₩16.95 Billion ≈ $11.49 Million	-51.36%
2012-12-31	₩34.84 Billion ≈ $23.61 Million	+90.07%
2011-12-31	₩18.33 Billion ≈ $12.42 Million	-7.59%
2010-12-31	₩19.84 Billion ≈ $13.45 Million	--

About Pharmicell

KO:005690 Korea Biotechnology

Market Cap

$470.89 Million

₩694.85 Billion KRW

Market Cap Rank

#12656 Global

#358 in Korea

Share Price

₩11580.00

Change (1 day)

-0.43%

52-Week Range

₩8760.00 - ₩20250.00

All Time High

₩25150.00